Avacta Reports Faridoxorubicin Results in Salivary Gland Cancer
Avacta says faridoxorubicin treatment nearly doubled progression-free survival and produced clinically meaningful tumor shrinkage in most patients with salivary gland cancers.
Avacta says faridoxorubicin treatment nearly doubled progression-free survival and produced clinically meaningful tumor shrinkage in most patients with salivary gland cancers.